웹2024년 5월 13일 · This review article published in the journal ONCOLOGY® looks at the successful clinical development of immunotherapies, PARP inhibitors, and antibody-drug conjugates for the management of metastatic triple-negative breast cancer and how these have improved the survival outcome of patients. Over the coming years, therapeutic … 웹2024년 9월 18일 · Background. T-DXd is a HER2-targeting antibody–drug conjugate approved for pts with advanced HER2+ mBC based on the results from DESTINY-Breast01 (NCT03248492). This is the first report of DESTINY-Breast03 (NCT03529110), a multicenter, open-label, randomized phase 3 study comparing the efficacy and safety of T-DXd vs T …

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple …

웹2024년 7월 25일 · The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months … 웹2024년 5월 20일 · Download Citation BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first-line metastatic triple ... sailability southwark

Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer NEJM

웹2024년 12월 10일 · “The therapeutic regimen of abemaciclib plus endocrine therapy is a major advance in the field of hormone receptor–positive breast cancer,” said the invited discussant of monarchE, Aditya Bardia, MD, MPH, of Massachusetts General Cancer Center, Harvard Medical School, Boston.“The last regulatory approval in the adjuvant hormone … 웹2024년 10월 25일 · The clinical benefit rate was 45% vs 9%, respectively. At data cutoff, 15 patients remained on sacituzumab govitecan vs none in the control arm. “The clinical benefit here confirms the use of sacituzumab govitecan as a standard therapy for patients with pretreated metastatic triple-negative breast cancer,” Dr. Bardia said. 웹2024년 6월 8일 · LBA1001 Background: HR+/HER2– disease is the most common subtype of metastatic breast cancer (MBC). Treatment includes sequential endocrine therapy combined with targeted agents followed by single-agent chemotherapy, with increasingly shorter durations of benefit. SG is an anti–Trop-2 antibody-drug conjugate approved for metastatic … sailability townsville